Showing 653 results

Filters Content type: News, Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Grazoprevir / elbasvir highly effective in previously untreated hepatitis C

News
24 April 2015
Hepatitis C treatment

Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease

News
24 April 2015
New & experimental hepatitis C treatment

Merck HCV combination achieves 90% cure in advanced cirrhosis

News
23 April 2015
New & experimental hepatitis C treatment

Merck HCV combination effective after failure of first generation of direct-acting antivirals

News
23 April 2015
Hepatitis C treatment

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Editor's pick
The Street
9 April 2015
New & experimental hepatitis C treatment

Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations

Editor's pick
Merck press release
9 April 2015
New & experimental hepatitis C treatment

At 50 Cents a Pill, Allergy Drug Could Best $1000 Sovaldi, Harvoni

Editor's pick
Healthline
9 April 2015
New & experimental hepatitis C treatment

FDA to review re-submitted Bristol-Myers hepatitis C drug

Editor's pick
Reuters
12 March 2015
Hepatitis & HIV

Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection

News
27 February 2015
New & experimental hepatitis C treatment

New hepatitis C treatments highly effective for HIV/HCV coinfected people

Editor's pick
HIVandHepatitis.com
26 February 2015
New & experimental hepatitis C treatment

Health News Review analysis of Reuters' coverage of new hepatitis C drugs

Editor's pick
Health News Review
13 February 2015
Access to healthcare

UNITAID: 2015 Hepatitis C medicines technology and market landscape

Editor's pick
UNITAID
13 February 2015
New & experimental hepatitis C treatment

FDA revokes breakthrough status for BMS hep C drug

Editor's pick
Fierce Biotech
11 February 2015
New & experimental hepatitis C treatment

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Editor's pick
Regulus Therapeutics press release
11 February 2015
New & experimental hepatitis C treatment

Promising data bodes well for all-Achillion hep C treatment

Editor's pick
Reuters
10 February 2015
New & experimental hepatitis C treatment

Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102

Editor's pick
Achillion press release
9 February 2015
New & experimental hepatitis C treatment

Merck says hepatitis C drugs to lose breakthrough status

Editor's pick
Reuters
5 February 2015
Pharmaceutical industry

AbbVie Inc stock drops after expectations for Viekira Pak fall short

Editor's pick
Bidness Etc
2 February 2015
New & experimental hepatitis C treatment

AbbVie next-generation hepatitis C drugs look promising in early studies

News
30 January 2015
Access to healthcare

Hepatitis C drug access: Europe is the new Africa

Editor's pick
HIV i-Base
30 January 2015
Access to healthcare

Petition: Equitable access to HCV drugs

Editor's pick
Petitionbuzz
30 January 2015
Access to healthcare

MSF response to Gilead announcement on inclusion of hepatitis C drug GS-5816 in voluntary licence

Editor's pick
Médecins Sans Frontières press release
27 January 2015
New & experimental hepatitis C treatment

Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent

Editor's pick
Gilead press release
27 January 2015
Access to healthcare

How India's Patent Office Destroyed Gilead's Global Game Plan

Editor's pick
Bloomberg Businessweek
19 January 2015